In brief, these studies identified several potential biomarkers that could be useful for identifying HER2-positive BC patients who may have a higher likelihood of resistance to anti-HER2 therapies and who could benefit from alternative or combined therapies. The gene discussed is ERBB2; the disease is breast cancer.